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Vaccine RepoRts
Background: two-dose varicella vaccination is recommended for opti-
mal control of varicella in populations with high (>90%) 1-dose coverage. 
optimal timing of the second dose may depend on whether breakthrough 
varicella results from primary vaccine failure (no protective immunity after 
vaccination) or secondary vaccine failure (waning protective immunity).
Methods: published literature (1995 to 2012) on vaccine failure after vari-
cella vaccination cited in pubMed and other online sources was reviewed.
Results: nineteen publications detailed 21 varicella outbreaks with break-
through varicella rates ranging from 0% to 42%; the publications showed 
no consistent trend between breakthrough varicella rate and time since 
 vaccination.
Conclusions: Literature to date indicates a relatively high rate of primary 
vaccine failure and limited evidence of secondary vaccine failure among 
1-dose varicella vaccine recipients, suggesting that a short interval between 
2 doses might be preferable in countries considering implementation of 
universal varicella vaccination to reduce breakthrough varicella. However, 
any potential disruption to well-established vaccination schedules should 
be considered.
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As a result of the societal and clinical impact of varicella, universal routine vaccination has been implemented in sev-
eral countries worldwide. in the United states, where 1-dose 
varicella universal routine vaccination was introduced in 1995, 
there have been substantial reductions in the number of varicella 
cases, varicella-related ambulatory visits, hospitalizations and 
deaths.1–3 outside of the United states, implementation of vari-
cella universal routine vaccination in Germany, italy (7 regions 
as of January 2012) and Uruguay has also resulted in decreased 
rates of hospitalizations and complications.4–8 However, in a 
recent review, 1-dose varicella vaccination was estimated to be 
only ~85% effective in preventing disease, resulting in cases of 
breakthrough varicella.9
Breakthrough varicella is defined as the appearance of a 
pruritic maculopapulovesicular rash with onset >42 days after vac-
cination without any other apparent cause.10 Whilst breakthrough 
varicella is generally milder (eg, involves fewer lesions, mostly 
papules, a lower rate of fever and shorter duration) than natural 
varicella, it is still a cause for concern due to varicella zoster virus 
(VZV) transmission from the breakthrough rash. additionally, it 
can establish latency to cause herpes zoster.11 Breakthrough vari-
cella is caused by primary or secondary vaccine failure. primary 
vaccine failure could be defined as the failure to seroconvert or the 
failure to mount a protective immune response after vaccination 
despite seroconversion, whereas secondary vaccine failure is the 
gradual waning of immunity over time.
in response to cases of breakthrough varicella, several 
countries have implemented recommendations for a 2-dose 
varicella vaccination schedule. indeed, the second dose of 
varicella vaccine has been shown to increase effectiveness from 
86% to 98%.12 However, the optimal timing for the second dose 
is currently unknown. Knowledge on the relative contributions 
of primary and secondary vaccine failure to the incidence of 
breakthrough varicella would influence decision making because 
a trend toward more primary than secondary vaccine failure would 
favor a shorter interval and vice versa. as more countries consider 
implementing varicella vaccination, it is important to know whether 
a short (months between doses) or a long (years between doses) 
immunization schedule will provide optimal control of the disease. 
therefore, a review of the literature has been carried out to assess 
the incidence and causes of varicella vaccine failure.
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Search Strategy and Selection Criteria
published literature (pubMed, conference abstracts, Google 
scholar and Medscape) on live-attenuated vaccine failure associated 
with 1 and 2 doses of varicella-containing vaccine was reviewed 
(1995 to January 2012). Limits included: english, humans, clini-
cal trials, randomized controlled trial, meta-analyses and reviews. 
search terms encompassed: “varicella vaccine failure,” “waning 
varicella immunity,” “breakthrough varicella,” “(measles mumps 
rubella varicella or MMRV) vaccine failure,” “varicella vaccine 
seroconversion” and “varicella vaccine catch-up.” exclusion cri-
teria included studies in immunocompromised patients, as the 
varicella vaccine is not routinely given to this patient group, and 
postoutbreak control.
cited articles were chosen on the relevance of their contents 
(eg, content on breakthrough varicella, varicella outbreaks, post-
vaccination antibody titers, vaccine failure, etc.), and each article 
was studied for references that were missed by the initial search. 
this was not intended as a systematic review.
One-dose Varicella Vaccine Effectiveness
since 1995, there have been 19 publications describing 21 
varicella outbreaks in vaccinated populations in day-care centers 
and elementary schools worldwide and 1 meta-analysis of 16 of 
these outbreaks (table 1).13–32 of these publications, 14 are from 
the United states where varicella universal routine vaccination 
has been employed since 1995. However, published outbreak 
reports represent just a small number of the outbreaks that actu-
ally occurred and most likely represent a bias toward outbreaks 
where issues occurred (ie, a large number of cases). indeed, a total 
of 190 outbreaks were reported to the centers for Disease control 
and prevention from 24 jurisdictions throughout the United states 
in 2004.33 this indicates that vaccine failure after 1-dose varicella 
vaccination is more prevalent than the published literature would 
suggest.
in published outbreaks, vaccination coverage rates for 1 
dose of varicella-containing vaccines were 30–97% (table 1).13–32 
in these studies, vaccine effectiveness varied from 20% to 100% 
against disease of any severity and 85.5% to 100% for moderate/
severe disease (table 1).13–32 Breakthrough varicella rates ranged 
from 0% to 42%, which appeared to have no association with vac-
cination coverage. For instance, the study with the lowest coverage 
(30%) showed the highest effectiveness (100%), as no vaccinated 
child developed breakthrough varicella15; however, this could be 
explained by study size as only 20 children attended the day-care 
center involved. it is therefore possible that vaccine coverage in a 
population experiencing an outbreak of varicella may not correlate 
with vaccine effectiveness.
outside of outbreak studies, the effectiveness of a single 
dose of vaccine against disease of any severity reported by vari-
cella surveillance in the United states and case-control studies 
falls in the range of 71% to 87%.2,9,12,34,35 a review of 19 stud-
ies (including outbreak reports) from the United states found that 
the median 1-dose effectiveness was 85%.9 additionally, 2 studies 
from israel indicated vaccine effectiveness of 88% and 92%.36,37 
one-dose vaccine effectiveness determined by a meta-analysis 
of 16 outbreaks worldwide was 72%.14 a large epidemiological 
study from taiwan that investigated the incidence of breakthrough 
varicella in over 1,000,000 vaccinated children found that 1-dose 
vaccine effectiveness was 82.6%.38 together, these data represent a 
rough average of 80% vaccine effectiveness for 1 dose of varicella 
vaccine against any varicella disease and an approximate vaccine 
failure rate of 20%. as with outbreak studies, effectiveness against 
severe/moderate disease was a lot higher than for disease of any 
severity.9,35,37
Vaccine Failure
Differentiating between primary and secondary vaccine 
failure in outbreak analyses is difficult, as measurement of anti-
body levels postvaccination cannot determine whether the affected 
individual had primary or secondary vaccine failure. additionally, 
secondary vaccine failure can have a similar clinical presentation 
to primary vaccine failure in those whose immunity has waned 
c ompletely.39
several risk factors have been proposed to increase varicella 
vaccine failure and are debated in the literature, including vaccine 
titer,40 immunization at a young age (particularly below 12–15 mon
ths),18,19,26,34,38,41–44 time since vaccination with other live virus vac-
cines,34,42,43 history of eczema,22,27,43 asthma23,26 vaccine brand30 and 
the use of oral or inhaled corticosteroids.26,34,42,43
a placebo-controlled trial conducted before the licensure 
of GlaxosmithKline Vaccine’s varicella vaccine set the scene for 
assessing the impact of varicella vaccination at population level.40 
in this study, infants and toddlers aged 10–30 months received 
placebo or varicella vaccine at (high) release titer (10,000–15,850 
plaque forming units [pfu]) or (low) expiry titer (630–1260 pfu). 
the seroconversion rates for the high and low titer vaccines were 
100% and 99.4%, respectively, when measured by immunofluores-
cence assay (iFa).
the protection rate over a period of 29 months (mean) was 
88% for the high titer and 55% for the low titer vaccines against 
any varicella disease. overall, vaccine efficacy was lower for those 
vaccinated at 10–18 months (64%) than those vaccinated at 19–24 
months of age (82%). these results indicated that vaccine titer and 
age at the time of vaccination are major determinants of clinical 
protection, which is lower than what could be expected from the 
high iFa seroconversion rates.
the importance of time since vaccination as a cause of vac-
cine failure is discussed further below.
Evidence for Primary Vaccine Failure
as shown in table 2,40,45–72 across all studies 0–24% of 
subjects failed to seroconvert after primary vaccination, depend-
ing on age group, vaccine titer and vaccine lot. importantly, the 
assays used to assess antibody titers vary between publications, 
which appeared to affect the outcome. For instance, assessment 
of seroconversion rates with enzyme-linked immunosorbent assay 
(eLisa) and iFa methods generally reported high seroconversion 
rates (>90%), whereas assessment with the validated fluorescent 
antibody to membrane antigen (FaMa) assay generally showed 
lower seroconversion rates of 76–84%.52,57 indeed, the FaMa 
assay is the only assay that has been validated in a real-life setting, 
where a positive titer correlated with protection following house-
hold exposure to varicella.73,74 additionally, 6-week postvaccination 
FaMa antibody titers have also been inversely correlated with the 
likelihood of developing breakthrough varicella over 10 years of 
follow-up.50 the high seroconversion rates (>90%) as assessed by 
eLisa and iFa methods have been proposed to be due to an initial 
burst of immunity after vaccination that may not be adequate to 
instigate a memory t-cell response.75 interestingly, this could be 
overcome by a higher dose of vaccine,40 or with a second dose of 
varicella vaccine, which has been shown to boost VZV-specific 
cell-mediated immune responses in children after vaccination.71,76
Using the glycoprotein eLisa employed by Merck & co., 
inc. (nJ) to measure VZV antibody concentrations, an arbitrary 
value of ≥5 glycoprotein eLisa units 6 weeks postvaccination 
correlates with a 3.5-fold reduced risk of breakthrough varicella, 
although this has never been verified in contact settings or correlated 
to the FaMa assay.53 additionally, the correlate of protection could 
not be ascertained from this study as it did not include a control 
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group. indeed, using this value as a threshold for protection, there 
is a wide range of primary vaccine failure (5–24%) after 1-dose 
varicella vaccination with a single brand.55,64 the reason for such 
variance is unclear.
of interest there is data suggesting that some children 
without detectable antibodies are still protected against infection 
by cell-mediated immunity.77 this would imply that antibodies do 
not play a direct role in immunity to VZV. indeed, it is unclear 
whether varicella antibodies play a direct role in vaccine-specific 
protection or whether they are just a surrogate marker for vaccine-
specific t-cell responses that accompany seroconversion.78 How-
ever, if 1-dose vaccine effectiveness is approximately 80% and 
seroconversion is a proxy marker for protection, most cases of 
breakthrough varicella can be accounted for by primary vaccine 
failure.
two case-control studies from the United states and china 
examined whether vaccine effectiveness is time dependent.34,79 
in the 8-year study from the United states, vaccine effectiveness 
dropped from 97% in the first year postvaccination to 86% in the 
second year and then remained stable.34 in the study from china, 
effectiveness was also shown to drop after the first year and then 
remain stable; however, this result was not statistically signifi-
cant.79 these effectiveness measures conflict with a 3-year retro-
spective study from taiwan where 81% of cases occurred during 
the first year postvaccination.80 However, these studies all indicate 
1-dose primary vaccine failure in populations with circulating 
VZV because the varicella breakthrough rate does not increase 
over time.
Evidence for Secondary Vaccine Failure
increased incidence and severity of breakthrough varicella 
with time is an indicator of secondary vaccine failure. of the 29 
publications that reported on breakthrough varicella rates with time 
(table 3),10,13,16,18,19,22,23,25–28,30,32,34,41,43,44,46,50,53,54,66,70,73,74,79–82 9 showed 
an increased risk with time of breakthrough varicella; this increased 
risk was generally observed around 4–5 years postvaccination. 
However, 7 of these publications were outbreak studies, which 
by design are based on limited population size and therefore not 
adequately powered to detect any drop in protection according to 
time since vaccination.
a large retrospective study of over 11,000 children found 
that time since vaccination is an important risk factor for break-
through varicella, with both incidence and severity increasing over 
a 10-year period.10 Whilst a strength of this study is that decreasing 
exposure levels were controlled for, this study did not use labora-
tory confirmation for cases of breakthrough varicella, which, as the 
disease tends to be very mild, can be confused with other causes 
of papulovesicular rashes. indeed, one of the strengths of the case-
control study conducted in the United states, which showed no sec-
ondary vaccine failure after the first year postvaccination, was that 
the authors required VZV Dna-positive samples from lesions for 
diagnosis of varicella.34
in a meta-analysis of varicella outbreaks, the authors mod-
eled vaccine effectiveness against time since vaccination (up to 
6 years) from 4 outbreaks.14 this analysis found that the pattern 
of vaccine effectiveness fitted models of waning immunity with a 
linear or exponential course.14 However, other longer-term studies 
TABLE 1. Publications and Characteristics of Selected Varicella Outbreaks in Vaccinated Populations









Buchholz1 199915 Los Angeles, USA URV Varivax 20 30 0 100 100
Arnedo-Pena 200613 Castellón, Spain Selective Varilrix 269 36 23 70 97
Miron 200528 Northern Israel Selective Varilrix 242 37 42 20 93
Izurieta 199723 Georgia, USA URV Varicella vaccine‡ 148 45 13 86 100
Lee 200425 Minnesota, USA URV Varivax 249 47 25 56 90
Marin 200527 Maine, USA URV Varivax 296 47 8 89 96
Tafuri 201031 Puglia, Italy URV Varilrix 102 54 13 82 NR
Spackova 201030 Various, Germany URV Varivax, Varilrix, 
Priorix-Tetra
631 62§ 21 62 [94]§ 89§
Dworkin 200218 Illinois, USA URV Varivax 209 68 6 88 NR
Lai 201124 Taipei, Taiwan URV Varivax 392 71 10 69–100¶ 85.5
Galil 200219 Pennsylvania, USA URV Varivax 131 73 36 44 86
Haddad1 200522 Utah, USA URV Varivax 558 77 4 87 90
Galil 200220 New Hampshire, USA URV Varivax 88 80 34 79 95
Centers for Disease 
Control and  
Prevention 200617
Nebraska, USA URV Varivax 142 81 13 81 93
Parker 200829 Maine, USA URV Varivax 341 81 13 87 100
Haddad2 200522 Utah, USA URV Varivax 924 83 5 87 99
Buchholz2 199915 Los Angeles, USA URV Varivax 39 87 24 71 93
Lopez 200626 Arkansas, USA URV Varivax 545 96§ 8 82 97
Centers for Disease 
Control and  
Prevention 200416
Michigan, USA URV Varivax 507 96 12 85 98
Gould 200921 Arkansas, USA URV Varivax 871 97 [39] 15 85 [89] 100
Tugwell 200432 Oregon, USA URV Varivax 218 97 9 72 NR
Bayer 200714 Meta-analysis Varivax — — — 73 NR
Data collated from the literature. Studies are listed in order of vaccine coverage. Superscript numbers (1 and 2) in references represent different cohorts within the same 
publication. Numbers in square brackets indicate 2-dose coverage and VE after 2 doses were available.
*Percentage of vaccinated children who develop breakthrough varicella.
†Effectiveness after 1 dose.
‡Commercial name not available.
§Coverage/VE include 2-dose vaccine recipients.
¶Across 3 school grades.
BV indicates breakthrough varicella; NR, not reported; URV, universal routine vaccination; VE, vaccine effectiveness.
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with up to 20 years of follow-up73,74 found long-term persistence of 
antibodies or have shown that the rate and severity of breakthrough 
varicella does not increase with time, suggesting a limited rate of 
secondary vaccine failure.41,50,66,74,81
Long-term studies do not indicate significant waning immu-
nity after varicella vaccination, as they have shown that there is no 
increase in breakthrough varicella between 4 and 8 years after vac-
cination.34,41,70,79 a mathematical model fitted to the rate of break-
through varicella in subjects of 3 clinical trials showed that, in the 
worst-case scenario (88% protected after vaccination, that is, 12% 
primary vaccine failure), the incidence of breakthrough varicella 
would increase in the first few years postvaccination and then pla-
teau at 3% per year for up to 6 years postvaccination.83 although 
this was extrapolated from a clinical trial which used a low titer 
vaccine lot currently not in production, it does appear to fit the pat-
terns observed in case-control studies.34,79
it should be emphasized that the results of long-term 
studies can be difficult to evaluate in areas where wild-type 
virus still circulates, as this can provide natural boosting to the 
immune system, reducing secondary vaccine failure. therefore, 
as circulating wild-type virus is reduced by universal routine 
vaccination, secondary vaccine failure could increase. in fact, 
time since vaccination was only identified as a risk factor for 
breakthrough varicella in 2002,19 7 years into the United states 
vaccination program. Moreover, it can be difficult to interpret 
long-term studies in countries where coverage rates change 
considerably over the years. as coverage rates plateau in the 
future, further long-term surveillance studies are required to fully 
assess the rate of secondary vaccine failure.
Evidence for Optimal Interval Between Doses
it has been suggested that high antibody titers are required 
for optimal protection against varicella, rather than seroconversion 
per se, and that 2 doses are required to achieve this.84,85 numerous 
studies have assessed antibody titers in children after administra-
tion of 2 doses of vaccine given at various intervals (4 weeks to 6 
years; table 4).49,58,62–65,71,86–93 these studies indicate that geometric 
mean antibody concentrations increase roughly 10-fold (range 5- to 
39-fold) after the second dose of vaccine in children, irrespective of 
timing between doses. such a large increase in antibody titers after 
the second dose suggests inadequate priming after the first dose 
and thus minimal induction of memory cells, resulting in vaccinees 
who are not fully protected after 1 dose.94
the boosting effect in geometric mean antibody 
concentrations observed with the short interval for the second 
dose is atypical of most live viral vaccines75 and suggests that 
TABLE 2. Varicella Zoster Virus Seroconversion/Seroresponse Rates 4–6 Weeks After 1 Dose of Varicella Vaccine in 
Children
Reference Vaccine(s) Total Children  Vaccinated
Seroconversion/ 
Seroresponse Rate (%) Assay* (Threshold)
Clements 199546 V (Varivax) 465 95 ELISA† and gpELISA†
Gatchalian 200447 V (Okavax) 100 96 Commercial ELISA (12 mIU/mL)
Michalik 200857 V (Varivax) 148 76 FAMA (>1:4 dilution)
Kim 201052 V (Varilrix, Varivax,  
Vari-L, SuduVax)
67 84
Johnson 199750 V (Varivax) 281 94–98‡ FAMA (>1:2 dilution)
Watson 199571 V (Varicella vaccine§) 419 100 gpELISA (≥0.3 units/mL)
Ngai 199658 V (Varivax) 2196 99 gpELISA (≥0.6 units/mL)
Li 200253 V (Varivax) 1164 99
Vessey 200170 V (Varivax) 1164 99
Watson 199672 V (Varivax) 111 100
Shinefield 200565 MMRV (ProQuad)  
or V (Varivax)
783 81–93 gpELISA (≥5.0 units/mL)
Shinefield 200564 MMRV (ProQuad)  
or V (Varivax)
480 91–99
Merck 200155 V (Varivax) 6889 76
Shinefield 200266 V (Varivax) 603 93–95¶
Silber 200767 V (Varivax) 3771 93
Nolan 200859 V (Varivax) 411 83
Gillet 200948 V IM or SC (Varivax) 752 86–88
Ramikissoon 199561 V (Varivax) 200 100 Indirect IFA (≥1:4 dilution)
Tan 199669 V (Varilrix) 191 98–100‡
Kanra 200051 V (Varilrix) 114 97
Barzaga 200245 V (Varilrix) 246 97
Nolan 200260 MMRV (Priorix-Tetra)  
or V (Varilrix)
160 93–96
Stück 200268 V (Varilrix) 61 96
Schuster 200863 V (Varilrix) 970 96
Gillet 200949 MMRV (Priorix-Tetra)  
or V (Varilrix)
458 96–100
Rümke 201162 MMRV (Priorix-Tetra) 372 98.4–98.9
Varis 199640 V (Varilrix) 325 99–100 Indirect IFA
Meruice 199656 V (Varilrix) 1372 99
Lim 199854 V (Varilrix) 181 99
Data collated from the literature.
*FAMA is the only assay validated in a real-life setting.
†No threshold for seroconversion/seroresponse specified.
‡Different vaccine lots.
§Commercial name not available.
¶Concomitant versus nonconcomitant administration with MMR.
gpELISA indicates glycoprotein ELISA; IM, intramuscular; SC, subcutaneous; V, monovalent varicella vaccine.
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an incomplete immune response is mounted after the first dose. 
in addition to the large booster effect of the second dose, the 
generally mild nature of breakthrough varicella would also seem to 
suggest that priming of the immune system takes place following 
vaccination.75,94 in this respect, a second dose would not be a 
booster for waning immunity but would instigate completion of the 
necessary immune response.
on this basis, the literature suggests that a second dose 
should be given soon after the first dose to cover the individuals 
with primary vaccine failure and those who did not mount an ade-
quate response for protection despite an initial antibody response 
(also termed primary vaccine failure by the definition laid out in 
this article). Furthermore, evidence also suggests that antibody 
titers fall during the first year postvaccination,52,57 which, even if 
this reflects a type of rapid waning immunity, indicates that the 
second dose should be given soon after the first because antibody 
titers are correlated with protection.50,53 therefore, administer-
ing the second dose of the vaccine within the second year of life 
may be optimal. the second dose should be given at least 4 weeks 
after the first, as clinical trials have not assessed shorter intervals 
(table 4).49,58,62,63,65,71,86–93 one study in adolescents and adults, who 
have always been given 2 doses of vaccine due to the lowered 
immunogenicity of the vaccine in this age group, found that delay-
ing the second dose to 8 weeks compared with 4 weeks induced 
higher antibody titers.95 additionally, a recent study of 2 doses 
of MMRV has shown that higher antibodies titers are induced if 
the second dose is given 12 months versus 4 weeks after the first 
dose (table 4).49,58,62,63,65,71,86–93 However, there were 2 cases of 
TABLE 3. Publications Showing Evidence For and Against Secondary Vaccine Failure






Time Since  
Vaccination  
a Risk Factor?
No evidence for secondary vaccine failure
Clements 199546 426 Varivax 5 2.7 19 No
Izurieta 199723* 148 Varicella vaccine† — — 13 No
Johnson 199750 281 Varivax 10 1.7 17 No
Takayama 199782 593 Oka strain† 8 1–4 34 No
Lim 199854 168 Varilrix 2.9 — 11 No
Ozaki 200081 973 Live varicella  
vaccine (Oka strain)‡
10 — 21 No
Saiman 200174 120 Varivax, Varilrix 20 — 10 No§
Vessey 200170 937 Varivax 7 0.2–2.3 7 No
Ampofo 200273 461 Varivax, Varilrix 20 — 9 No§
Dworkin 200218* 209 Varivax — — 6 No
Li 200253 1087 Varivax 7 0.2–2.2 6 No
Shinefield 200266 603 Varivax 5 1.1–1.4 6–7 No
Tseng 200380 1248 Varivax 2.6 2.1–2.8 2 No—First year after 
vaccination only
Vázquez 200434¶ 1008 Varivax 8 — — No—First year after 
vaccination only
Marin 200527* 296 Varivax — — 8 No
Lopez 200626*║ 545 Varivax — — 8 No
Black 200841 7449 Varivax 8 — 16 No—First 4 yr after 
vaccination only
Lee 200843 9025 Varivax 5 6–8 5 No
Spackova 201030*║ 631 Varivax, Varilrix,  
Priorix-Tetra
4.6 — 21 No
Fu 201079¶ 1000 Varilrix, Shanghai, 
Changchun
5 — — No
Evidence for secondary vaccine failure
Galil 200219* 131 Varivax — — 26 Yes
Centers for Disease Control and  
Prevention 200416*
507 Varivax — — 12 Yes—Time since  
vaccination >4 yr
Lee 200425* 249 Varivax — — 25 Yes—Time since  
vaccination >5 yr
Tugwell 200432* 218 Varivax — — 9 Yes—Time since  
vaccination >5 yr
Haddad 200522* 1482 Varivax — — 5 Yes—Time since  
vaccination >5 yr
Miron 200528* 242 Varilrix — — 42 Yes—Time since  
vaccination >2 yr
Arnedo-Pena 200613* 269 Varilrix — — 23 Yes—Time since  
vaccination >25 mo
Chaves 200710 11,356 Varivax 10 — 10 Yes
Kurugol 201144 1683 Varilrix and Okavax 10 3–63 28 Yes—Time since  
vaccination >5 yr
Data collated from the literature.
*Outbreak studies.
†Commercial name not available.
‡Biken Institute, Osaka, Japan.
§Vaccinees were adults who had received 1, 2 or 3 doses of the vaccine.
¶Case-control study.
║Vaccinees were children who had received 1 or 2 doses of the vaccine.
BV indicates breakthrough varicella.
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breakthrough varicella 5 and 10 months after the first dose in the 
12-month interval group, and no cases in the 4-week interval group, 
despite a similar rate of varicella contact.62
Implementation of a Short-interval 2-dose 
Schedule
short-interval 2-dose varicella immunization schedules 
should reduce the period of time that a child with primary vac-
cine failure is unprotected, reducing the risk of breakthrough 
disease. there are a number of different options for implementa-
tion of short-interval 2-dose varicella vaccination in the second 
year of life: 1) vaccination with 2 doses of monovalent vaccine; 
2) vaccination with 2 doses of MMRV vaccine; 3) vaccination 
with a combination of 2 doses of MMR and varicella vaccine and/
or MMRV. However, implementation of a short interval between 
doses should always be evaluated with respect to the overall vacci-
nation schedule. a public health evaluation of the advantages and 
disadvantages of alternative vaccination schedules should be care-
fully performed.
For ease of scheduling, a combination of MMRV or mono-
valent vaccines can be used to allow flexibility for the administra-
tion of 2 doses of varicella vaccine. For instance, in Germany, both 
MMRV and monovalent vaccines are licensed under 2-dose sched-
ules.96 this option is especially pertinent for the United states, 
where the second dose of MMR is currently suggested for children 
aged 4–6 years.97 in this instance, the use of a monovalent vaccine 
would allow the second dose to be administered in the second year 
of life. this is currently permitted in the United states varicella 
vaccination schedule as long as there is a minimum of 3 months 
between doses.98 another possibility that may be considered to 
implement the short-interval 2-dose schedule for varicella is shift-
ing the age at which the second dose of MMR is administered from 
4−6 years to 18 months of age. this option may minimize admin-
istration costs for the immunization program (less patient visits/
administration costs, for example, needles and reduced time dedi-
cated by healthcare professionals) and will help support improved 
coverage for both MMR and varicella vaccination.
Reduction in Risk With Short- Versus Long-interval 
Immunization Schedules
assuming no waning immunity and breakthrough varicella rates 
of 1–3% per year (table 3),10,13,16,18,19,22,23,25–28,30,32,34,41,43,44,46,50,53,54,66,70,73,74,79–
82 changing the timing of the second dose from age 4–6 years to the 
second year of life could prevent around 2-fold cumulative cases of 
breakthrough varicella. Undoubtedly, this figure is an overestimation as 
increasing varicella vaccination coverage would reduce the opportunity 
for contracting the disease; however, a high primary vaccine failure 
rate could allow continued circulation of the virus. additionally, 
implementation of a short immunization schedule would be especially 
important for countries that introduce varicella vaccination because 
wild-type virus circulates more in those countries than in countries 
that have already reduced incidence of the disease due to varicella 
vaccination.
Effectiveness of 2-dose Schedules
two-dose schedules have been implemented in a variety of 
countries worldwide, including the United states and Germany. 
Unlike the United states, Germany employs short-interval vari-
cella vaccination where both doses are given in the second year of 
life. Recent outbreak reports from Germany and the United states 
have varied on the effectiveness of a second dose of varicella vac-
cine. in Germany, a second dose of MMRV within the second year 
of life (66% second-dose coverage) increased vaccine effective-
ness from 62% to 94% in outbreak situations.30 Long-term follow-
up of clinical trials where 2 doses were given in a short interval 
(3 months between doses) also showed that 2 doses provide more 
protection than a single dose.90 in the United states, where a longer 
schedule is used, 2 studies have shown that a second dose of vac-
cine increases vaccine effectiveness by up to 98%.12,99 the short 
schedule should theoretically protect children earlier in life as it 
allows early revaccination of children with primary vaccine fail-
ure.98 as the duration of immunity to 2 doses of varicella vaccine is 
currently unknown, continued surveillance and prospective studies 
are required.
TABLE 4. Geometric Mean Antibody Concentrations After 2 Doses of  VZV-containing Vaccines in Children
Reference Dose 1 Dose 2 Dose Interval Fold Increase in GMC From  First to Second Dose
Schuster 200863 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 6 wk 23.7
Czajka 200986 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 6–8 wk 26.6*
Gillet 200949 MMRV(Priorix-Tetra) V(Varilrix) 6–8 wk 12.6–14.1
Gillet 200949 MMR+V(Priorix and Varilrix) V(Varilrix) 6–8 wk 9.8–13.1
Knuf 200689 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 6–8 wk >20
Kuter 200490 V(Varivax) V(Varivax) 12 wk 11.0
Ngai 199658 V(Varivax) V(Varivax) 12 wk 11.6
Shinefield 200565 MMRV(ProQuad) MMRV(ProQuad) 12 wk 29.4–39.4†
Shinefield 200564 MMRV(ProQuad) MMRV(ProQuad) 12 wk 45.2
Goh 200787 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 12 wk 10.0
Goh 200787 MMR+V(Priorix and Varilrix) MMR+V(Priorix and Varilrix) 12 wk 5.0
Reisinger 200691 MMR+V(M-M-R-II and Varivax) MMRV(ProQuad) 3 yr 12.4
Reisinger 200691 MMR+V(M-M-R-II and Varivax) MMR+V(M-M-R-II and Varivax) 3 yr 8.5
Vesikari 200792 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 5 yr 9.8
Watson 199571 V(Varicella vaccine‡) V(Varicella vaccine‡) 4–6 yr 8.5
Halperin 200988 MMR+V(Priorix and Varilrix) MMRV(Priorix-Tetra) 6 wk to 5 yr 27.2
Halperin 200988 MMR+V(Priorix and Varilrix) MMR+V(Priorix and Varilrix) 6 wk to 5 yr 26.2
Rümke 201162 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 4 wk 7.8
Rümke 201162 MMRV(Priorix-Tetra) MMRV(Priorix-Tetra) 1 yr 22.6
Data collated from the literature.
*Pooled analysis of 3 studies.63,89,93
†Dose range study for MMRV vaccine.
‡Commercial name not available.
GMC indicates geometric mean antibody concentration; V, monovalent varicella vaccine.
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Conclusion
all published evidence (1995 to 2012) for varicella vac-
cine failure strongly supports a 2-dose schedule in order to obtain 
effective control of the disease.12,29,30,90,100 a review of the literature 
indicated a relatively high rate of primary vaccine failure among 
recipients of 1-dose varicella vaccine and limited convincing evi-
dence of secondary vaccine failure. Furthermore, vaccine effective-
ness decreases after the first year postvaccination and then remains 
stable, a pattern predictive of primary vaccine failure. this suggests 
that the second dose of varicella vaccine should be given as close to 
the first as possible (minimum interval of 4 weeks based on clini-
cal trials), to prevent a large number of people remaining vulner-
able to infection and to reduce the risk of breakthrough varicella. 
However, individual countries should consider how shortening 
the interval between doses could impact second-dose vaccination 
coverage, especially if this warrants an additional visit to the doc-
tor for vaccination. a comparison of vaccine efficacy between the 
United states and Germany, which employ different varicella vac-
cination schedules, is warranted in the future. our findings need to 
be placed in the context of an important limitation of the selection 
criteria employed in this review. published outbreak reports rep-
resented only a small number of the varicella outbreaks that actu-
ally occurred. our review did not assess vaccine failure from the 
varicella outbreaks reported only to the centers for Disease con-
trol and prevention. therefore, we expect that vaccine failure after 
1-dose varicella vaccination is more prevalent than what published 
literature would suggest. to conclude, we propose that a short inter-
val between 2 doses of the varicella vaccine might be preferable 
to reduce breakthrough varicella, especially in countries that will 
introduce varicella vaccination and where the wild-type virus cir-
culates predominantly.
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Erratum
serotype childhood invasive pneumococcal Disease has Unique characteristics compared to Disease caused by other Streptococ-
cus pneumoniae serotypes: eRRatUM
in the article on page 614, volume 32, issue 6 of The Pediatric Infectious Disease Journal there was an error in the title. the article 
title should appear as “serotypeº1 childhood invasive pneumococcal Disease has Unique characteristics compared to Disease 
caused by other Streptococcus pneumoniae serotypes”. please note the inclusion of the 1. 
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